Equities Analysts Offer Predictions for Marrone Bio Innovations Inc’s Q1 2019 Earnings (MBII)

Equities Analysts Offer Predictions for Marrone Bio Innovations Inc’s Q1 2019 Earnings (MBII)

Marrone Bio Innovations Inc (NASDAQ:MBII) – Investment analysts at Jefferies Financial Group issued their Q1 2019 EPS estimates for Marrone Bio Innovations in a report released on Monday, April 29th, Zacks Investment Research reports. Jefferies Financial Group analyst L. Alexander expects that the basic materials company will earn ($0.04) per share for the quarter. Jefferies Financial Group also issued estimates for Marrone Bio Innovations’ Q2 2019 earnings at ($0.05) EPS and Q3 2019 earnings at ($0.05) EPS.

Marrone Bio Innovations (NASDAQ:MBII) last posted its quarterly earnings data on Thursday, May 9th. The basic materials company reported ($0.04) EPS for the quarter, hitting the consensus estimate of ($0.04). Marrone Bio Innovations had a negative net margin of 82.82% and a negative return on equity of 123.95%. The business had revenue of $8.72 million for the quarter, compared to analyst estimates of $6.18 million.

Separately, National Securities reaffirmed a “buy” rating and issued a $2.50 target price on shares of Marrone Bio Innovations in a report on Friday, May 10th.
Marrone Bio Innovations stock traded down $0.03 during trading hours on Tuesday, hitting $1.65. The stock had a trading volume of 54,742 shares, compared to its average volume of 128,944. The company has a debt-to-equity ratio of 2.47, a quick ratio of 1.47 and a current ratio of 1.94. The stock has a market capitalization of $186.01 million, a PE ratio of -7.86 and a beta of -0.12. Marrone Bio Innovations has a 12-month low of $1.10 and a 12-month high of $2.18.

A number of institutional investors have recently modified their holdings of the business. BlackRock Inc. raised its holdings in Marrone Bio Innovations by 0.5% in the fourth quarter. BlackRock Inc. now owns 2,800,519 shares of the basic materials company’s stock worth $4,117,000 after buying an additional 14,014 shares during the last quarter. Northern Trust Corp raised its holdings in Marrone Bio Innovations by 3.1% in the first quarter. Northern Trust Corp now owns 538,681 shares of the basic materials company’s stock worth $824,000 after buying an additional 16,161 shares during the last quarter. Rhumbline Advisers raised its holdings in Marrone Bio Innovations by 44.3% in the fourth quarter. Rhumbline Advisers now owns 68,021 shares of the basic materials company’s stock worth $100,000 after buying an additional 20,882 shares during the last quarter. Geode Capital Management LLC raised its holdings in Marrone Bio Innovations by 5.8% in the fourth quarter. Geode Capital Management LLC now owns 443,611 shares of the basic materials company’s stock worth $652,000 after buying an additional 24,460 shares during the last quarter. Finally, Raymond James & Associates purchased a new position in Marrone Bio Innovations in the first quarter worth about $41,000. 42.18% of the stock is owned by institutional investors and hedge funds.

About Marrone Bio Innovations

Marrone Bio Innovations, Inc provides bio-based pest management and plant health products primarily for agricultural and water markets in the United States and internationally. It offers herbicides; fungicides; nematicides; insecticides; algaecides for algae control; molluscicides for mussel and snail control; plant growth and stress regulators; and water treatment products for various applications, such as hydroelectric and thermoelectric power generation, industrial applications, drinking water, aquaculture, irrigation, and recreation.

Share:
error: Content is protected !!